Guided Therapeutics to Report Q3 2012 Results and Hold Conference Call

  Guided Therapeutics to Report Q3 2012 Results and Hold Conference Call

Business Wire

NORCROSS, Ga. -- November 01, 2012

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid
and painless testing platform that uses biophotonics for the early detection
of disease, today announced that it is scheduled to report financial results
for its third quarter ended September 30, 2012 on Tuesday, November 13, 2012,
after the market closes.

Guided Therapeutics will hold a conference call at 11:00 a.m. EST Wednesday,
November 14, 2012, to discuss its financial results and corporate
developments. Interested parties are invited to listen to the call live over
the Internet at or The live call is also available by dialing (888)
510-1786 or for international callers (719) 325-2308.

A replay of the teleconference will be available on A replay will also be available, until
November 21, 2012, by dialing (877) 870-5176 or for international callers
(858) 384-5517, and using pin number 3514457.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a rapid
and painless testing platform for the early detection of disease based on its
patented biophotonic technology that utilizes light to detect disease at the
cellular level. The Company’s first planned product is the LuViva^® Advanced
Cervical Scan, a non-invasive device used to detect cervical disease instantly
and at the point of care. In a multi-center clinical trial, with women at risk
for cervical disease, the technology was able to detect cervical cancer up to
two years earlier than conventional modalities, according to published
reports. Guided Therapeutics has also entered into a partnership with Konica
Minolta to develop a non-invasive test for the early detection of esophageal
cancer using the technology platform. For more information, visit:

The Guided Therapeutics LuViva^® Advanced Cervical Scan is an investigational
device and is limited by federal law to investigational use. LuViva, the wave
logo and "Early detection, better outcomes" are registered trademarks owned by
Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject
areas discussed in this news release that are not historical or current facts
deal with potential future circumstances and developments. The discussion of
such matters and subject areas is qualified by the inherent risks and
uncertainties surrounding future expectations generally and also may
materially differ from Guided Therapeutics’ actual future experience involving
any of or more of such matters and subject areas. Such risks and uncertainties
include those related to the early stage of products in development, the
uncertainty of market acceptance of products, the uncertainty of development
or effectiveness of distribution channels, the intense competition in the
medical device industry, the uncertainty of capital to develop products, the
uncertainty of regulatory approval of products, dependence on licensed
intellectual property, as well as those that are more fully described from
time to time under the heading “Risk Factors” in Guided Therapeutics’ reports
filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K
for the fiscal year ended December 31, 2011, and subsequent quarterly reports.


Cameron Associates
Alison Ziegler, 212-554-5469
Guided Therapeutics
Bill Wells, 770-242-8723 Ext. 241
Press spacebar to pause and continue. Press esc to stop.